• Tempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral in vivo CAR-T platform.
• Option covers a portfolio led by a BCMA/GPRC5D dual-targeting candidate in Phase 1 dose escalation for relapsed or refractory multiple myeloma.
• Early observations at the highest evaluable dose showed in vivo CAR-T generation and expansion.
• As of Aug. 25, 2026, no Grade 3+ cytokine release syndrome or neurotoxicity was reported at evaluated doses.
• Deal adds a lentiviral approach alongside Tempest’s CD7-targeted lipid nanoparticle platform, planned to enter the clinic later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-394492), on September 17, 2026, and is solely responsible for the information contained therein.